Ultimately, the DEA prevents medical marijuana from moving forward
Nowadays, health experts and researchers are starting to better understand the benefits of medical marijuana. However, obstacles arise from the DEA’s meddling and the FDA’s rather complex approval system. When organizations submit investigational new drug reports for clinical trials of new medications, the FDA has 2 months to review and approve the trial. The Center for Drug Evaluation and Research, which is a research center controlled by the FDA, reviews the work performed by outside agents and provides recommendations to the FDA relating to labelling and dosages. Due to the fact that the FDA relies on outside research organizations, research on medical marijuana is subject to state laws. Therefore, the illegal status of medical marijuana makes conducting clinical trials extremely difficult, if not impossible.
The DEA poses an even greater limitation than the FDA, as it blocks research efforts on a frequent basis. According to the agency, marijuana is classified as a Schedule I substance, making is unacceptable for medical use and a high potential for abuse. However, the main paradox lies within the government held patent number 6630507, which recognizes that marijuana has medicinal properties. This specific government patent acknowledges the many health benefits of medical marijuana, yet the very same government has classified marijuana as a substance with “no currently accepted medical use”, therefore making the entire situation contradictory.